Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.

Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD.

J Am Heart Assoc. 2018 Feb 10;7(4). pii: e007283. doi: 10.1161/JAHA.117.007283. No abstract available.

2.

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.

Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA.

Br J Clin Pharmacol. 2018 May;84(5):876-887. doi: 10.1111/bcp.13520. Epub 2018 Mar 5.

3.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003800. doi: 10.1161/CIRCHEARTFAILURE.116.003800.

4.

[Granuloma annulare: an atypical site].

Badaoui A, Mugnier P, Vignon Penamen MD.

Ann Dermatol Venereol. 2014 Dec;141(12):810-1. doi: 10.1016/j.annder.2014.07.009. Epub 2014 Sep 11. French. No abstract available.

PMID:
25433939
5.

Structure-function relationships of CarO, the carbapenem resistance-associated outer membrane protein of Acinetobacter baumannii.

Catel-Ferreira M, Coadou G, Molle V, Mugnier P, Nordmann P, Siroy A, Jouenne T, Dé E.

J Antimicrob Chemother. 2011 Sep;66(9):2053-6. doi: 10.1093/jac/dkr267. Epub 2011 Jun 23.

PMID:
21705362
6.

OXA-134, a naturally occurring carbapenem-hydrolyzing class D beta-lactamase from Acinetobacter lwoffii.

Figueiredo S, Poirel L, Seifert H, Mugnier P, Benhamou D, Nordmann P.

Antimicrob Agents Chemother. 2010 Dec;54(12):5372-5. doi: 10.1128/AAC.00629-10. Epub 2010 Sep 13.

7.

Characterization and PCR-based replicon typing of resistance plasmids in Acinetobacter baumannii.

Bertini A, Poirel L, Mugnier PD, Villa L, Nordmann P, Carattoli A.

Antimicrob Agents Chemother. 2010 Oct;54(10):4168-77. doi: 10.1128/AAC.00542-10. Epub 2010 Jul 26.

8.

Carbapenemase-producing Acinetobacter baumannii, Algeria.

Drissi M, Poirel L, Mugnier PD, Baba Ahmed Z, Nordmann P.

Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1457-8. doi: 10.1007/s10096-010-1011-2. Epub 2010 Jul 15. No abstract available.

PMID:
20632052
9.

Decoding accuracy in eRF1 mutants and its correlation with pleiotropic quantitative traits in yeast.

Merritt GH, Naemi WR, Mugnier P, Webb HM, Tuite MF, von der Haar T.

Nucleic Acids Res. 2010 Sep;38(16):5479-92. doi: 10.1093/nar/gkq338. Epub 2010 May 5.

10.

Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii.

Mugnier PD, Poirel L, Naas T, Nordmann P.

Emerg Infect Dis. 2010 Jan;16(1):35-40. doi: 10.3201/eid1601.090852.

11.

ISCR2, another vehicle for bla(VEB) gene acquisition.

Poirel L, Mugnier PD, Toleman MA, Walsh TR, Rapoport MJ, Petroni A, Nordmann P.

Antimicrob Agents Chemother. 2009 Nov;53(11):4940-3. doi: 10.1128/AAC.00414-09. Epub 2009 Aug 24.

12.

Diversity of plasmid-mediated carbapenem-hydrolysing oxacillinases among carbapenem-resistant Acinetobacter baumannii isolates from Kingdom of Bahrain.

Mugnier PD, Bindayna KM, Poirel L, Nordmann P.

J Antimicrob Chemother. 2009 May;63(5):1071-3. doi: 10.1093/jac/dkp052. Epub 2009 Feb 27. No abstract available.

PMID:
19252183
13.

Functional analysis of insertion sequence ISAba1, responsible for genomic plasticity of Acinetobacter baumannii.

Mugnier PD, Poirel L, Nordmann P.

J Bacteriol. 2009 Apr;191(7):2414-8. doi: 10.1128/JB.01258-08. Epub 2009 Jan 9.

14.

Carbapenem-resistant and OXA-23-producing Acinetobacter baumannii isolates in the United Arab Emirates.

Mugnier P, Poirel L, Pitout M, Nordmann P.

Clin Microbiol Infect. 2008 Sep;14(9):879-82. doi: 10.1111/j.1469-0691.2008.02056.x.

15.

Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.

Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, Faccone D, Galas M, Drugeon H, Cattoir V, Nordmann P.

Antimicrob Agents Chemother. 2007 Jun;51(6):2179-84. Epub 2007 Apr 9.

16.

Efficacy of dideoxynucleosides against human foamy virus and relationship to its reverse transcriptase amino acid sequence and structure.

Yvon-Groussin A, Mugnier P, Bertin P, Grandadam M, Agut H, Huraux JM, Calvez V.

J Virol. 2001 Aug;75(15):7184-7.

17.

The crystal structure of human eukaryotic release factor eRF1--mechanism of stop codon recognition and peptidyl-tRNA hydrolysis.

Song H, Mugnier P, Das AK, Webb HM, Evans DR, Tuite MF, Hemmings BA, Barford D.

Cell. 2000 Feb 4;100(3):311-21.

18.

Translation termination and its regulation in eukaryotes: recent insights provided by studies in yeast.

Mugnier P, Tuite MF.

Biochemistry (Mosc). 1999 Dec;64(12):1360-6. Review.

19.

Site-directed mutagenesis of residues 164, 170, 171, 179, 220, 237 and 242 in PER-1 beta-lactamase hydrolysing expanded-spectrum cephalosporins.

Bouthors AT, Delettré J, Mugnier P, Jarlier V, Sougakoff W.

Protein Eng. 1999 Apr;12(4):313-8.

PMID:
10325401
20.

Novel OXA-10-derived extended-spectrum beta-lactamases selected in vivo or in vitro.

Mugnier P, Casin I, Bouthors AT, Collatz E.

Antimicrob Agents Chemother. 1998 Dec;42(12):3113-6.

21.

Carbapenems as inhibitors of OXA-13, a novel, integron-encoded beta-lactamase in Pseudomonas aeruginosa.

Mugnier P, Podglajen I, Goldstein FW, Collatz E.

Microbiology. 1998 Apr;144 ( Pt 4):1021-31.

PMID:
9579076
22.

A novel extended-spectrum TEM-type beta-lactamase (TEM-52) associated with decreased susceptibility to moxalactam in Klebsiella pneumoniae.

Poyart C, Mugnier P, Quesne G, Berche P, Trieu-Cuot P.

Antimicrob Agents Chemother. 1998 Jan;42(1):108-13.

23.

Carbapenem resistance in a clinical isolate of Citrobacter freundii.

Mainardi JL, Mugnier P, Coutrot A, Buu-Hoï A, Collatz E, Gutmann L.

Antimicrob Agents Chemother. 1997 Nov;41(11):2352-4.

24.

A TEM-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E.

Antimicrob Agents Chemother. 1996 Nov;40(11):2488-93.

25.

[beta-Lactamases of Branhamella catarrhalis and their phenotypic implications].

Chaïbi EB, Mugnier P, Kitzis MD, Goldstein FW, Acar JF.

Res Microbiol. 1995 Nov-Dec;146(9):761-71. Review. French.

PMID:
8584798
26.

[Phenotypes of resistance to antibiotics of Acinetobacter baumannii. Impact on therapeutic orientation].

Ygout JF, Pasteau C, Mugnier P, Berlioux J, Daguet GL.

Pathol Biol (Paris). 1988 Mar;36(3):245-9. French.

PMID:
3283688
27.

Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years.

Najean Y, Mugnier P, Dresch C, Rain JD.

Br J Haematol. 1987 Nov;67(3):285-91.

PMID:
3689694
28.

[Should treatment be discontinued in the case of a lepromatous leprosy patient who follows treatment very irregularly?].

Mugnier P.

Acta Leprol. 1983 Apr-Jun;1(2):105-8. French. No abstract available.

PMID:
6356764
29.

[101 cases of lepromatous leprosy under observation without treatment after stable negativation. Evaluation 20 years later].

Mugnier P, Rollier M, Rollier R.

Acta Leprol. 1982 Jan-Jun;(86-87):185-8. French. No abstract available.

PMID:
6815987

Supplemental Content

Loading ...
Support Center